VTYX Q2 2023 Earnings — Ventyx Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

VTYXVentyx Biosciences, Inc.

$1B

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$57M

Net Income

-$53M

EPS (Diluted)

$-0.91

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$49M

Free Cash Flow

-$49M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$349M

Total Liabilities

$21M

Stockholders' Equity

$328M

Cash & Equivalents

$52M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$57M	-$20M	-180.2%
Net Income	-$53M	-$20M	-166.0%